Maintaining Public Trust in Biobanking - Time for True Transparency?
In the digital environment, access and transparency are becoming increasingly common concerns. As technical industries, pharma and biotech have of course been involved in this debate. One of the recent developments in this area has been a policy paper published in Science by VU University Amsterdam, bioethicist Jeantine E. Lunshof, King’s College London political scientist Dr. Barbara Prainsack and Pharma IQ interviewee George M. Church, Professor of Genetics at Harvard. The paper a...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.